866-997-4948(US-Canada Toll Free)

Stroke - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 519 Pages

Stroke - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke Pipeline Review, H2 2016, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 10, 21, 14, 1, 89 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 35 and 4 molecules, respectively.Stroke.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 7
Stroke Overview 8
Therapeutics Development 9
Stroke - Therapeutics under Development by Companies 11
Stroke - Therapeutics under Investigation by Universities/Institutes 19
Stroke - Pipeline Products Glance 21
Stroke - Products under Development by Companies 24
Stroke - Products under Investigation by Universities/Institutes 33
Stroke - Companies Involved in Therapeutics Development 36
Stroke - Therapeutics Assessment 128
Drug Profiles 145
Stroke - Dormant Projects 466
Stroke - Discontinued Products 481
Stroke - Product Development Milestones 485
Appendix 498

List of Tables
Number of Products under Development for Stroke, H2 2016 29
Number of Products under Development for Stroke - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Development by Companies, H2 2016 (Contd..1) 32
Number of Products under Development by Companies, H2 2016 (Contd..2) 33
Number of Products under Development by Companies, H2 2016 (Contd..3) 34
Number of Products under Development by Companies, H2 2016 (Contd..4) 35
Number of Products under Development by Companies, H2 2016 (Contd..5) 36
Number of Products under Development by Companies, H2 2016 (Contd..6) 37
Number of Products under Development by Companies, H2 2016 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H2 2016 39
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 40
Comparative Analysis by Late Stage Development, H2 2016 41
Comparative Analysis by Clinical Stage Development, H2 2016 42
Comparative Analysis by Early Stage Development, H2 2016 43
Products under Development by Companies, H2 2016 44
Products under Development by Companies, H2 2016 (Contd..1) 45
Products under Development by Companies, H2 2016 (Contd..2) 46
Products under Development by Companies, H2 2016 (Contd..3) 47
Products under Development by Companies, H2 2016 (Contd..4) 48
Products under Development by Companies, H2 2016 (Contd..5) 49
Products under Development by Companies, H2 2016 (Contd..6) 50
Products under Development by Companies, H2 2016 (Contd..7) 51
Products under Development by Companies, H2 2016 (Contd..8) 52
Products under Investigation by Universities/Institutes, H2 2016 53
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 54
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 55
Stroke - Pipeline by AB Science SA, H2 2016 56
Stroke - Pipeline by Acticor Biotech, H2 2016 57
Stroke - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2016 58
Stroke - Pipeline by Addex Therapeutics Ltd, H2 2016 59
Stroke - Pipeline by advanceCor GmbH, H2 2016 60
Stroke - Pipeline by Affibody AB, H2 2016 61
Stroke - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 62
Stroke - Pipeline by Anavex Life Sciences Corp, H2 2016 63
Stroke - Pipeline by Angion Biomedica Corp, H2 2016 64
Stroke - Pipeline by Antoxis Ltd, H2 2016 65
Stroke - Pipeline by APT Therapeutics, Inc., H2 2016 66
Stroke - Pipeline by ArmaGen Inc, H2 2016 67
Stroke - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 68
Stroke - Pipeline by AstraZeneca Plc, H2 2016 69
Stroke - Pipeline by Athersys Inc, H2 2016 70
Stroke - Pipeline by Bayer AG, H2 2016 71
Stroke - Pipeline by Bioasis Technologies Inc, H2 2016 72
Stroke - Pipeline by Biogen Inc, H2 2016 73
Stroke - Pipeline by Boehringer Ingelheim GmbH, H2 2016 74
Stroke - Pipeline by Cardax Inc, H2 2016 75
Stroke - Pipeline by Cellular Biomedicine Group Inc, H2 2016 76
Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H2 2016 77
Stroke - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 78
Stroke - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 79
Stroke - Pipeline by D-Pharm Ltd, H2 2016 80
Stroke - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 81
Stroke - Pipeline by DiaMedica Inc, H2 2016 82
Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 83
Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 84
Stroke - Pipeline by Fina Biotech, H2 2016 85
Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 86
Stroke - Pipeline by Glialogix Inc, H2 2016 87
Stroke - Pipeline by Glucox Biotech AB, H2 2016 88
Stroke - Pipeline by Green Cross Corp, H2 2016 89
Stroke - Pipeline by Huons Co Ltd, H2 2016 90
Stroke - Pipeline by International Stem Cell Corp, H2 2016 91
Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 92
Stroke - Pipeline by JN-International Medical Corp, H2 2016 93
Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 94
Stroke - Pipeline by LegoChem Biosciences Inc, H2 2016 95
Stroke - Pipeline by Les Laboratoires Servier SAS, H2 2016 96
Stroke - Pipeline by Living Cell Technologies Ltd, H2 2016 97
Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H2 2016 98
Stroke - Pipeline by M et P Pharma AG, H2 2016 99
Stroke - Pipeline by Magnus Life Ltd, H2 2016 100
Stroke - Pipeline by Mapreg SAS, H2 2016 101
Stroke - Pipeline by Mast Therapeutics Inc, H2 2016 102
Stroke - Pipeline by Medestea Research & Production SpA, H2 2016 103
Stroke - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 104
Stroke - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 105
Stroke - Pipeline by Neuralstem Inc, H2 2016 106
Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 107
Stroke - Pipeline by Neurofx Inc, H2 2016 108
Stroke - Pipeline by Neuronax SAS, H2 2016 109
Stroke - Pipeline by Neurotec Pharma SL, H2 2016 110
Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2016 111
Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H2 2016 112
Stroke - Pipeline by New World Laboratories Inc, H2 2016 113
Stroke - Pipeline by NoNO Inc, H2 2016 114
Stroke - Pipeline by NuvOx Pharma LLC, H2 2016 115
Stroke - Pipeline by Omeros Corp, H2 2016 116
Stroke - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 117
Stroke - Pipeline by PharmatrophiX, Inc., H2 2016 118
Stroke - Pipeline by Pharmaxis Ltd, H2 2016 119
Stroke - Pipeline by Pharmicell Co Ltd, H2 2016 120
Stroke - Pipeline by Phoenix Biotechnology Inc, H2 2016 121
Stroke - Pipeline by Phylogica Ltd, H2 2016 122
Stroke - Pipeline by PhytoHealth Corp, H2 2016 123
Stroke - Pipeline by Pluristem Therapeutics Inc, H2 2016 124
Stroke - Pipeline by Primary Peptides, Inc., H2 2016 125
Stroke - Pipeline by Q Therapeutics Inc, H2 2016 126
Stroke - Pipeline by QR Pharma Inc, H2 2016 127
Stroke - Pipeline by ReCyte Therapeutics Inc, H2 2016 128
Stroke - Pipeline by Regenera Pharma Ltd, H2 2016 129
Stroke - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2016 130
Stroke - Pipeline by Remedy Pharmaceuticals Inc, H2 2016 131
Stroke - Pipeline by ReNeuron Group Plc, H2 2016 132
Stroke - Pipeline by SanBio Inc, H2 2016 133
Stroke - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 134
Stroke - Pipeline by Shin Poong PharmCo Ltd, H2 2016 135
Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2016 136
Stroke - Pipeline by Stemedica Cell Technologies Inc, H2 2016 137
Stroke - Pipeline by SynZyme Technologies LLC, H2 2016 138
Stroke - Pipeline by Targazyme Inc, H2 2016 139
Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 140
Stroke - Pipeline by TikoMed AB, H2 2016 141
Stroke - Pipeline by vasopharm GmbH, H2 2016 142
Stroke - Pipeline by Verseon Corp, H2 2016 143
Stroke - Pipeline by Vicore Pharma AB, H2 2016 144
Stroke - Pipeline by Virogenomics BioDevelopment Inc, H2 2016 145
Stroke - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2016 146
Stroke - Pipeline by Zocere Inc, H2 2016 147
Assessment by Monotherapy Products, H2 2016 148
Number of Products by Stage and Target, H2 2016 150
Number of Products by Stage and Mechanism of Action, H2 2016 156
Number of Products by Stage and Route of Administration, H2 2016 162
Number of Products by Stage and Molecule Type, H2 2016 164
Stroke - Dormant Projects, H2 2016 486
Stroke - Dormant Projects (Contd..1), H2 2016 487
Stroke - Dormant Projects (Contd..2), H2 2016 488
Stroke - Dormant Projects (Contd..3), H2 2016 489
Stroke - Dormant Projects (Contd..4), H2 2016 490
Stroke - Dormant Projects (Contd..5), H2 2016 491
Stroke - Dormant Projects (Contd..6), H2 2016 492
Stroke - Dormant Projects (Contd..7), H2 2016 493
Stroke - Dormant Projects (Contd..8), H2 2016 494
Stroke - Dormant Projects (Contd..9), H2 2016 495
Stroke - Dormant Projects (Contd..10), H2 2016 496
Stroke - Dormant Projects (Contd..11), H2 2016 497
Stroke - Dormant Projects (Contd..12), H2 2016 498
Stroke - Dormant Projects (Contd..13), H2 2016 499
Stroke - Dormant Projects (Contd..14), H2 2016 500
Stroke - Discontinued Products, H2 2016 501
Stroke - Discontinued Products (Contd..1), H2 2016 502
Stroke - Discontinued Products (Contd..2), H2 2016 503
Stroke - Discontinued Products (Contd..3), H2 2016 504

List of Figures
Number of Products under Development for Stroke, H2 2016 29
Number of Products under Development for Stroke - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Investigation by Universities/Institutes, H2 2016 39
Comparative Analysis by Late Stage Development, H2 2016 41
Comparative Analysis by Clinical Stage Development, H2 2016 42
Comparative Analysis by Early Stage Products, H2 2016 43
Assessment by Monotherapy Products, H2 2016 148
Number of Products by Top 10 Targets, H2 2016 149
Number of Products by Stage and Top 10 Targets, H2 2016 149
Number of Products by Top 10 Mechanism of Actions, H2 2016 155
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 155
Number of Products by Top 10 Routes of Administration, H2 2016 161
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 161
Number of Products by Top 10 Molecule Types, H2 2016 163
Number of Products by Stage and Top 10 Molecule Types, H2 2016 163

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *